Barbara J Fisher1, Chen Hu2, David R Macdonald3, Glenn J Lesser4, Stephen W Coons5, David G Brachman6, Samuel Ryu7, Maria Werner-Wasik8, Jean-Paul Bahary9, Junfeng Liu10, Arnab Chakravarti11, Minesh Mehta12. 1. London Regional Cancer Program, London, Ontario, Canada. Electronic address: barbara.fisher@lhsc.on.ca. 2. Radiation Therapy Oncology Group-Statistical Center, Philadelphia, Pennsylvania. 3. London Regional Cancer Program, London, Ontario, Canada. 4. Wake Forest University Baptist Medical Center, Winston-Salem, North Carolina. 5. Barrow Neurological Institute, Phoenix, Arizona. 6. Arizona Oncology Services Foundation, Phoenix, Arizona. 7. Henry Ford Hospital, Detroit, Michigan. 8. Thomas Jefferson University Hospital Center, Philadelphia, Pennsylvania. 9. Centre Hospitalier de l'Université de Montréal-Notre Dame, Montreal, Quebec, Canada. 10. GCE Solutions, Inc., Bloomington, Illinois. 11. The Ohio State University, The James, Columbus, Ohio. 12. University of Maryland Medical Systems, Baltimore, Maryland.
Abstract
PURPOSE: Radiation Therapy Oncology Group (RTOG) 0424 was a phase 2 study of a high-risk low-grade glioma (LGG) population who were treated with temozolomide (TMZ) and radiation therapy (RT), and outcomes were compared to those of historical controls. This study was designed to detect a 43% increase in median survival time (MST) from 40.5 to 57.9 months and a 20% improvement in 3-year overall survival (OS) rate from 54% to 65% at a 10% significance level (1-sided) and 96% power. METHODS AND MATERIALS: Patients with LGGs with 3 or more risk factors for recurrence (age ≥40 years, astrocytoma histology, bihemispherical tumor, preoperative tumor diameter of ≥6 cm, or a preoperative neurological function status of >1) were treated with RT (54 Gy in 30 fractions) and concurrent and adjuvant TMZ. RESULTS: From 2005 to 2009, 129 evaluable patients (75 males and 54 females) were accrued. Median age was 49 years; 91% had a Zubrod score of 0 or 1; and 69%, 25%, and 6% of patients had 3, 4, and 5 risk factors, respectively. Patients had median and minimum follow-up examinations of 4.1 years and 3 years, respectively. The 3-year OS rate was 73.1% (95% confidence interval: 65.3%-80.8%), which was significantly improved compared to that of prespecified historical control values (P<.001). Median survival time has not yet been reached. Three-year progression-free survival was 59.2%. Grades 3 and 4 adverse events occurred in 43% and 10% of patients, respectively. One patient died of herpes encephalitis. CONCLUSIONS: The 3-year OS rate of 73.1% for RTOG 0424 high-risk LGG patients is higher than that reported for historical controls (P<.001) and the study-hypothesized rate of 65%.
PURPOSE: Radiation Therapy Oncology Group (RTOG) 0424 was a phase 2 study of a high-risk low-grade glioma (LGG) population who were treated with temozolomide (TMZ) and radiation therapy (RT), and outcomes were compared to those of historical controls. This study was designed to detect a 43% increase in median survival time (MST) from 40.5 to 57.9 months and a 20% improvement in 3-year overall survival (OS) rate from 54% to 65% at a 10% significance level (1-sided) and 96% power. METHODS AND MATERIALS: Patients with LGGs with 3 or more risk factors for recurrence (age ≥40 years, astrocytoma histology, bihemispherical tumor, preoperative tumor diameter of ≥6 cm, or a preoperative neurological function status of >1) were treated with RT (54 Gy in 30 fractions) and concurrent and adjuvant TMZ. RESULTS: From 2005 to 2009, 129 evaluable patients (75 males and 54 females) were accrued. Median age was 49 years; 91% had a Zubrod score of 0 or 1; and 69%, 25%, and 6% of patients had 3, 4, and 5 risk factors, respectively. Patients had median and minimum follow-up examinations of 4.1 years and 3 years, respectively. The 3-year OS rate was 73.1% (95% confidence interval: 65.3%-80.8%), which was significantly improved compared to that of prespecified historical control values (P<.001). Median survival time has not yet been reached. Three-year progression-free survival was 59.2%. Grades 3 and 4 adverse events occurred in 43% and 10% of patients, respectively. One patient died of herpes encephalitis. CONCLUSIONS: The 3-year OS rate of 73.1% for RTOG 0424 high-risk LGGpatients is higher than that reported for historical controls (P<.001) and the study-hypothesized rate of 65%.
Authors: Thomas B Daniels; Paul D Brown; Sara J Felten; Wenting Wu; Jan C Buckner; Robert M Arusell; Walter J Curran; Ross A Abrams; David Schiff; Edward G Shaw Journal: Int J Radiat Oncol Biol Phys Date: 2011-05-05 Impact factor: 7.038
Authors: Thierry Gorlia; Wenting Wu; Meihua Wang; Brigitta G Baumert; Minesh Mehta; Jan C Buckner; Edward Shaw; Paul Brown; Roger Stupp; Evanthia Galanis; Denis Lacombe; Martin J van den Bent Journal: Neuro Oncol Date: 2013-09-18 Impact factor: 12.300
Authors: Edward F Chang; Aaron Clark; Randy L Jensen; Mark Bernstein; Abhijit Guha; Giorgio Carrabba; Debabrata Mukhopadhyay; Won Kim; Linda M Liau; Susan M Chang; Justin S Smith; Mitchel S Berger; Michael W McDermott Journal: J Neurosurg Date: 2009-08 Impact factor: 5.115
Authors: Roger Stupp; Monika E Hegi; Warren P Mason; Martin J van den Bent; Martin J B Taphoorn; Robert C Janzer; Samuel K Ludwin; Anouk Allgeier; Barbara Fisher; Karl Belanger; Peter Hau; Alba A Brandes; Johanna Gijtenbeek; Christine Marosi; Charles J Vecht; Karima Mokhtari; Pieter Wesseling; Salvador Villa; Elizabeth Eisenhauer; Thierry Gorlia; Michael Weller; Denis Lacombe; J Gregory Cairncross; René-Olivier Mirimanoff Journal: Lancet Oncol Date: 2009-03-09 Impact factor: 41.316
Authors: G Kaloshi; A Benouaich-Amiel; F Diakite; S Taillibert; J Lejeune; F Laigle-Donadey; M-A Renard; W Iraqi; A Idbaih; S Paris; L Capelle; H Duffau; P Cornu; J-M Simon; K Mokhtari; M Polivka; A Omuro; A Carpentier; M Sanson; J-Y Delattre; K Hoang-Xuan Journal: Neurology Date: 2007-05-22 Impact factor: 9.910
Authors: Santosh Kesari; David Schiff; Jan Drappatz; Debra LaFrankie; Lisa Doherty; Eric A Macklin; Alona Muzikansky; Sandro Santagata; Keith L Ligon; Andrew D Norden; Abigail Ciampa; Joanna Bradshaw; Brenda Levy; Gospova Radakovic; Naren Ramakrishna; Peter M Black; Patrick Y Wen Journal: Clin Cancer Res Date: 2009-01-01 Impact factor: 12.531
Authors: Edward G Shaw; Meihua Wang; Stephen W Coons; David G Brachman; Jan C Buckner; Keith J Stelzer; Geoffrey R Barger; Paul D Brown; Mark R Gilbert; Minesh P Mehta Journal: J Clin Oncol Date: 2012-07-30 Impact factor: 44.544
Authors: John K Wiencke; Shichun Zheng; Nanette Jelluma; Tarik Tihan; Scott Vandenberg; Tanja Tamgüney; Rachel Baumber; Ramon Parsons; Kathleen R Lamborn; Mitchel S Berger; Margaret R Wrensch; Daphne Adele Haas-Kogan; David Stokoe Journal: Neuro Oncol Date: 2007-05-15 Impact factor: 12.300
Authors: C Houillier; X Wang; G Kaloshi; K Mokhtari; R Guillevin; J Laffaire; S Paris; B Boisselier; A Idbaih; F Laigle-Donadey; K Hoang-Xuan; M Sanson; J-Y Delattre Journal: Neurology Date: 2010-10-26 Impact factor: 11.800
Authors: Erica H Bell; Peixin Zhang; Barbara J Fisher; David R Macdonald; Joseph P McElroy; Glenn J Lesser; Jessica Fleming; Arup R Chakraborty; Ziyan Liu; Aline P Becker; Denise Fabian; Kenneth D Aldape; Lynn S Ashby; Maria Werner-Wasik; Eleanor M Walker; Jean-Paul Bahary; Young Kwok; H Michael Yu; Nadia N Laack; Christopher J Schultz; Heidi J Gray; H Ian Robins; Minesh P Mehta; Arnab Chakravarti Journal: JAMA Oncol Date: 2018-10-01 Impact factor: 31.777
Authors: Michael Wahl; Joanna J Phillips; Annette M Molinaro; Yi Lin; Arie Perry; Daphne A Haas-Kogan; Joseph F Costello; Manisha Dayal; Nicholas Butowski; Jennifer L Clarke; Michael Prados; Sarah Nelson; Mitchel S Berger; Susan M Chang Journal: Neuro Oncol Date: 2017-02-01 Impact factor: 12.300